Open Access
Subscription Access
The Impact of Drugs on Pregnant Women: Navigating the Complex Landscape
Abstract
Pregnancy is an important period during which the health and well_ being of both the mother and the developing fetus are of utmost importance. The use of a very few drugs during pregnancy needs careful consideration, as certain drugs show profound effects on maternal and fetal health teratogenic compounds namely thalidomide and isotretinoin can influence birth defective. Exposure to a very few drugs particularly during specific stages of fetal development may lead to structural abnormalities. Many pregnant women may need ongoing treatment for pre_ existing situations namely diabetes, hypertension or epilepsy. In such cases, health care providers in a careful manner weigh the benefits of regulating material health against potential risks to the fetus. Over_the_Counter (OTC ) medications may show consequences particularly during pregnancy. Non steroidal anti-inflammatory drugs ( NSAIDs ), may be related to the complications, especially in the later stages of pregnancy. Pregnant women are advised to go for consultation with their healthcare providers particularly before taking any OTC medications. Open communication between the patient and healthcare provider is an important aspects for informed decision_ making. Exposure to substances namely alcohol, tobacco and illicit drugs may result in developmental issues, pre term birth as well as long_ term cognitive deficits. Organizations namely U.S. Food and Drug Administration ( FDA ) categorize drugs dependent on their safety profiles especially for pregnant women, arranging arranging a valuable resource especially forvhealth care providers to make I formed decisions. Regular prenatal check_ups play an important rolevfor monitoring the health of both the mother and developing fetus. Finally it is concluded that navigating the complex landscape of drugs during pregnancy needsva collaborative approach between healthcare providers and expectant mother's.
References
Thalidomide Teratogenic Effects Linked to Degradation of SALL4: After 60 years, researchers have now shed light on the mechanism underlying thalidomide's devastating teratogenic effects. Am J Med Genet A. 2018 Dec;176(12):2538-2539. [PubMed]
Alem G, Awuonda M, Haastrup D, Anyiwo A, Daftary M, Wingate L, Ettienne E. Evaluation of knowledge of the new Pregnancy and Lactation Labeling Rule among pharmacists and physicians. J Am Pharm Assoc (2003). 2022 Mar-Apr;62(2):427-431. [PubMed]
Kennedy MLH. Medication management of bipolar disorder during the reproductive years. Ment Health Clin. 2017 Nov;7(6):255-261. [PMC free article] [PubMed]
Tomson T, Sha L, Chen L. Management of epilepsy in pregnancy: What we still need to learn. Epilepsy Behav Rep. 2023;24:100624. [PMC free article] [PubMed]
Ornoy A. Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy. Reprod Toxicol. 2006 Aug;22(2):214-26. [PubMed]
Mantovani A, Calamandrei G. Delayed developmental effects following prenatal exposure to drugs. Curr Pharm Des. 2001 Jun;7(9):859-80. [PubMed]
Kennedy D, Koren G. Valproic acid use in psychiatry: issues in treating women of reproductive age. J Psychiatry Neurosci. 1998 Sep;23(4):223-8. [PMC free article] [PubMed]
Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol. 2009 Jul;28(1):1-10. [PubMed]
Nie Q, Su B, Wei J. Neurological teratogenic effects of antiepileptic drugs during pregnancy. Exp Ther Med. 2016 Oct;12(4):2400-2404. [PMC free article] [PubMed]
DiLiberti JH, Farndon PA, Dennis NR, Curry CJ. The fetal valproate syndrome. Am J Med Genet. 1984 Nov;19(3):473-81. [PubMed]
Andrade C. Valproate in Pregnancy: Recent Research and Regulatory Responses. J Clin Psychiatry. 2018 May/Jun;79(3) [PubMed]
Hansen DK, Dial SL, Terry KK, Grafton TF. In vitro embryotoxicity of carbamazepine and carbamazepine-10, 11-epoxide. Teratology. 1996 Jul;54(1):45-51. [PubMed]
Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A Review of Antibiotic Use in Pregnancy. Pharmacotherapy. 2015 Nov;35(11):1052-62. [PubMed]
Cunnington M, Tennis P., International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology. 2005 Mar 22;64(6):955-60. [PubMed]
Tennis P, Eldridge RR., International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia. 2002 Oct;43(10):1161-7. [PubMed]
Dozet D, Burd L, Popova S. Screening for Alcohol Use in Pregnancy: a Review of Current Practices and Perspectives. Int J Ment Health Addict. 2023;21(2):1220-1239. [PMC free article] [PubMed]
Yonkers KA, Howell HB, Gotman N, Rounsaville BJ. Self-report of illicit substance use versus urine toxicology results from at-risk pregnant women. J Subst Use. 2011 Oct 01;16(5):372-389. [PMC free article] [PubMed]
Wong S, Ordean A, Kahan M., MATERNAL FETAL MEDICINE COMMITTEE. FAMILY PHYSICIANS ADVISORY COMMITTEE. MEDICO-LEGAL COMMITTEE. AD HOC REVIEWERS. SPECIAL CONTRIBUTORS. Substance use in pregnancy. J Obstet Gynaecol Can. 2011 Apr;33(4):367-384. [PubMed]
Reisfield GM, Teitelbaum SA, Jones JT. Poppy Seed Consumption May Be Associated with Codeine-Only Urine Drug Test Results. J Anal Toxicol. 2023 Mar 21;47(2):107-113. [PubMed]
Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health Syst Pharm. 2010 Aug 15;67(16):1344-50. [PubMed]
Tobacco and Nicotine Cessation During Pregnancy: ACOG Committee Opinion, Number 807. Obstet Gynecol. 2020 May;135(5):e221-e229. [PubMed]
DeVido J, Bogunovic O, Weiss RD. Alcohol use disorders in pregnancy. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):112-21. [PMC free article] [PubMed]
Bacon O, Robert S, VandenBerg A. Evaluating nursing satisfaction and utilization of the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar). Ment Health Clin. 2016 Jun;6(3):114-119. [PMC free article] [PubMed]
Rodriguez CE, Klie KA. Pharmacological treatment of opioid use disorder in pregnancy. Semin Perinatol. 2019 Apr;43(3):141-148. [PubMed]
Towers CV, Katz E, Weitz B, Visconti K. Use of naltrexone in treating opioid use disorder in pregnancy. Am J Obstet Gynecol. 2020 Jan;222(1):83.e1-83.e8. [PubMed]
Short VL, Hand DJ, MacAfee L, Abatemarco DJ, Terplan M. Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States. J Subst Abuse Treat. 2018 Jun;89:67-74. [PubMed]
Patrick SW, Richards MR, Dupont WD, McNeer E, Buntin MB, Martin PR, Davis MM, Davis CS, Hartmann KE, Leech AA, Lovell KS, Stein BD, Cooper WO. Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder. JAMA Netw Open. 2020 Aug 03;3(8):e2013456. [PMC free article] [PubMed]
Klaman SL, Isaacs K, Leopold A, Perpich J, Hayashi S, Vender J, Campopiano M, Jones HE. Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National Guidance. J Addict Med. 2017 May/Jun;11(3):178-190. [PMC free article] [PubMed]
Minozzi S, Amato L, Jahanfar S, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2020 Nov 09;11(11):CD006318. [PMC free article] [PubMed]
Noormohammadi A, Forinash A, Yancey A, Crannage E, Campbell K, Shyken J. Buprenorphine Versus Methadone for Opioid Dependence in Pregnancy. Ann Pharmacother. 2016 Aug;50(8):666-72. [PubMed]
Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010 Dec 09;363(24):2320-31. [PMC free article] [PubMed]
Park EM, Meltzer-Brody S, Suzuki J. Evaluation and management of opioid dependence in pregnancy. Psychosomatics. 2012 Sep-Oct;53(5):424-32. [PMC free article] [PubMed]
Bakhireva LN, Holbrook BD, Shrestha S, Leyva Y, Ashley M, Cano S, Lowe J, Stephen JM, Leeman L. Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age. Early Hum Dev. 2019 Jan;128:69-76. [PMC free article] [PubMed]
Smith J, Lafferty M, Boelig RC, Carola D, Adeniyi-Jones S, Kraft WK, Greenspan JS, Aghai ZH. Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome? Am J Perinatol. 2022 Jul;39(10):1138-1144. [PubMed]
Pizarro D, Habli M, Grier M, Bombrys A, Sibai B, Livingston J. Higher maternal doses of methadone does not increase neonatal abstinence syndrome. J Subst Abuse Treat. 2011 Apr;40(3):295-8. [PubMed]
Holmes AP, Schmidlin HN, Kurzum EN. Breastfeeding Considerations for Mothers of Infants with Neonatal Abstinence Syndrome. Pharmacotherapy. 2017 Jul;37(7):861-869. [PubMed]
Chu L, McGrath JM, Qiao J, Brownell E, Recto P, Cleveland LM, Lopez E, Gelfond J, Crawford A, McGlothen-Bell K. A Meta-Analysis of Breastfeeding Effects for Infants With Neonatal Abstinence Syndrome. 2022 Jan-Feb 01Nurs Res. 71(1):54-65. [PMC free article] [PubMed]
Graves L. Cannabis and breastfeeding. Paediatr Child Health. 2020 Jun;25(Suppl 1):S26-S28. [PMC free article] [PubMed]
Mast EE. Mother-to-infant hepatitis C virus transmission and breastfeeding. Adv Exp Med Biol. 2004;554:211-6. [PubMed]
Bansaccal N, Van der Linden D, Marot JC, Belkhir L. HIV-Infected Mothers Who Decide to Breastfeed Their Infants Under Close Supervision in Belgium: About Two Cases. Front Pediatr. 2020;8:248. [PMC free article] [PubMed]
Refbacks
- There are currently no refbacks.